Form 4: Biodesix Director Strobeck Receives Equity Grants

Biodesix Director Matthew Strobeck was granted 6,804 Restricted Stock Units and options to purchase 6,354 shares of common stock on January 2, 2026.

Summary

• Matthew Strobeck, a Director of Biodesix Inc. (BDSX), received equity grants on January 2, 2026.
• The grants include 6,804 Restricted Stock Units (RSUs) and options to purchase 6,354 shares of common stock.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• The RSUs will vest in four equal installments on March 31, June 30, September 30, and December 31, 2026, generally subject to Mr. Strobeck's continued service with the Issuer.
• The shares of common stock underlying the deferred RSUs will be issued to Mr. Strobeck following his separation from service with the Issuer.
• The stock options have an exercise price of $6.46 per share.
• The stock options will vest in four substantially equal installments on March 31, June 30, September 30, and December 31, 2026, generally subject to Mr. Strobeck's continued service with the Issuer.
• The stock options have an expiration date of January 1, 2036.

Sentiment

Score: 7

Explanation: The filing reports routine equity compensation for a director, which is a standard practice to align management and shareholder interests. It does not indicate any significant operational or financial news that would drastically alter sentiment.

Positives

• The grant of equity awards to a director aligns their financial interests with those of the company's shareholders, promoting long-term value creation.
• The vesting schedule for both RSUs and stock options encourages the director's continued service and commitment to the company's performance over time.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The equity grants to Matthew Strobeck, a Director, represent a form of related party compensation, which is a standard and transparent practice for public companies.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of the director's interests with shareholder value through equity ownership. The grants represent a standard component of director compensation, with minimal expected dilutive effect.
• Management: Matthew Strobeck's compensation package is enhanced, potentially increasing his motivation and retention within the company.

Next Steps

• Vesting of Restricted Stock Units in four equal installments on March 31, June 30, September 30, and December 31, 2026.
• Vesting of Stock Options in four substantially equal installments on March 31, June 30, September 30, and December 31, 2026.
• Issuance of shares underlying deferred RSUs to Matthew Strobeck following his separation from service with the Issuer.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for a director and does not provide new information that would warrant a change in investment recommendation. It reflects standard corporate governance practices for aligning director incentives with shareholder interests, which is generally a neutral event for stock price.

Keywords

Biodesix, BDSX, Matthew Strobeck, Director, SEC Form 4, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Insider Transaction, Compensation